Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. - Páez, David; Tobeña, María; Fernández-Plana, Julen; Sebio, Ana; Virgili, Anna C.; Cirera, Lluís; Barnadas, Agustí; Riera, Pau; Sullivan, Ivana; Salazar, Juliana (British Journal of Cancer, 2019)